rabi
viru
rabv
belong
famili
rhabdovirida
genu
lyssaviru
caus
acut
enceph
mammal
lyssavirus
envelop
rna
virus
helic
symmetri
display
outer
surfac
virion
envelop
g
protein
target
antigen
antibodi
rabv
first
fourteen
lyssaviru
speci
identifi
date
dietzgen
et
al
addit
yet
unclassifi
put
speci
name
lleida
bat
lyssaviru
llebv
arechiga
ceballo
et
al
accord
viral
genet
distanc
two
major
phylogroup
defin
phylogroup
includ
speci
rabv
european
bat
lyssaviru
type
type
duvenhag
viru
duvv
australian
bat
lyssaviru
ablv
aravan
viru
arav
khujand
viru
khuv
bokeloh
bat
lyssaviru
bblv
irkut
viru
irkv
phylogroup
ii
includ
lago
bat
viru
lbv
mokola
viru
mokv
shimoni
bat
viru
shibv
remain
virus
west
caucasian
bat
viru
wcbv
ikoma
lyssaviru
ikov
includ
either
phylogroup
temporarili
assign
put
phylogroup
iii
iv
respect
bourhi
et
al
amengu
et
al
hooper
et
al
badran
et
al
kuzmin
et
al
marston
et
al
current
thought
infect
lyssaviru
speci
culmin
viral
enceph
clinic
indistinguish
caus
rabv
ultim
result
human
anim
death
rabv
found
almost
ubiquit
worldwid
differ
anim
reservoir
occasion
spillov
event
host
includ
human
although
almost
fatal
follow
onset
symptom
rabi
control
anim
reservoir
mass
vaccin
prevent
appropri
prophylact
treatment
human
expos
viru
approxim
million
peopl
per
year
treat
exposur
rabi
case
follow
bite
infect
anim
peopl
estim
die
year
mainli
africa
china
india
rabi
case
worldwid
occur
children
fook
et
al
hampson
et
al
howev
true
burden
lyssavirus
develop
countri
unknown
larg
mallewa
et
al
human
rabi
prevent
achiev
either
prophylaxi
expos
rabv
prophylaxi
pep
recommend
prevent
advanc
infect
thu
clinic
diseas
howev
must
administ
earli
possibl
accord
world
health
organ
world
health
organ
pep
includ
treatment
wound
administr
rabi
vaccin
alon
combin
rabi
immunoglobulin
rig
categori
ii
iii
exposur
respect
particular
patient
categori
iii
exposur
receiv
rig
administ
around
wound
site
four
five
dose
vaccin
two
type
rig
current
avail
pep
human
equin
rabi
immunoglobulin
hrig
erig
respect
dose
hrig
recommend
iukg
bodi
weight
correspond
mgkg
erig
f
product
recommend
dose
iukg
bodi
weight
higher
dose
rig
shown
reduc
vaccin
efficaci
atanasiu
et
al
archer
dierk
sike
cabasso
et
al
wiktor
et
al
cabasso
hrig
wide
use
develop
countri
consid
safer
erig
high
cost
hrig
limit
avail
hamper
wide
use
countri
particularli
africa
dodet
africa
rabi
bureau
afroreb
moreov
vaccin
hrig
erig
confer
protect
infect
lyssaviru
speci
protect
thought
invers
relat
genet
distanc
rabv
vaccin
strain
brook
et
al
hanlon
et
al
et
al
thu
search
replac
hrig
strongli
encourag
world
health
organ
end
mous
human
monoclon
antibodi
develop
last
decad
two
product
advanc
clinic
trial
name
produc
crucel
base
combin
two
antibodi
call
bakker
et
al
goudsmit
et
al
produc
mass
biolog
serum
institut
india
base
singl
monoclon
antibodi
sloan
et
al
nagarajan
et
al
howev
rabv
isol
neutral
monoclon
antibodi
identifi
marissen
et
al
kuzimina
et
al
find
highlight
challeng
perform
phase
trial
risk
monoclon
pep
failur
pose
seriou
ethic
concern
inde
lack
broad
rabv
coverag
develop
recent
halt
still
phase
develop
india
thu
select
develop
safe
effect
monoclon
pep
rabv
infect
paramount
import
identifi
neutral
monoclon
antibodi
abl
recogn
g
protein
sequenc
rabv
lineag
previous
describ
viral
target
corti
lanzavecchia
combin
two
antibodi
bind
differ
antigen
site
rabv
g
protein
abl
broadli
neutral
rabv
lyssaviru
isol
significantli
reduc
risk
pep
failur
order
isol
broadli
neutral
antibodi
rabv
isol
also
lyssavirus
sera
rabv
vaccine
screen
presenc
high
titer
antibodi
bind
rabv
isol
g
protein
elisa
fig
highest
bind
titer
test
abil
neutral
panel
pseudotyp
lyssavirus
repres
rabv
lyssavirus
isol
phylogroup
ii
iii
virus
fig
appendix
tabl
hrig
includ
refer
expect
sampl
neutral
albeit
variabl
titer
isol
rabv
neutral
profil
lyssaviru
speci
vari
consider
donor
test
case
speci
neutral
interest
note
hrig
show
modest
activ
phylogroup
speci
phylogroup
ii
iii
virus
memori
b
cell
four
vaccine
select
presenc
serum
antibodi
capabl
broadli
neutral
multipl
lyssaviru
speci
immort
viru
ebv
cpg
previous
describ
traggiai
et
al
cultur
supernat
test
use
rabv
pseudotyp
neutral
assay
cell
five
hundr
human
monoclon
antibodi
isol
abil
neutral
pseudotyp
rabv
human
monoclon
antibodi
select
high
neutral
potenc
rabv
pseudotyp
viru
concentr
antibodi
neutral
viral
infect
rang
ngml
appendix
tabl
antibodi
use
differ
vh
vl
gene
slight
bia
toward
carri
heavi
chain
region
differ
length
variabl
load
somat
mutat
appendix
tabl
hrig
three
human
monoclon
antibodi
clinic
develop
use
refer
expect
antibodi
bound
rabv
g
protein
elisa
order
understand
whether
cognat
epitop
conform
rabv
g
protein
run
gel
reduc
condit
probe
western
blot
isol
human
monoclon
antibodi
except
antibodi
bind
rabv
g
protein
reduc
condit
thu
suggest
epitop
recogn
case
conform
appendix
tabl
competit
studi
perform
determin
spatial
proxim
conform
epitop
recogn
select
neutral
monoclon
antibodi
two
refer
antibodi
previous
shown
recogn
g
protein
antigen
site
iii
respect
marissen
et
al
de
kruif
et
al
therefor
use
assay
probe
map
specif
antibodi
result
shown
fig
use
cluster
test
antibodi
group
antibodi
assign
antigen
site
group
accord
competit
reciproc
competit
interestingli
bind
antigen
site
antibodi
g
protein
enhanc
bind
sever
site
antibodi
assign
antigen
site
iii
group
accord
competit
reciproc
competit
show
partial
competit
antibodi
bind
site
differ
site
iii
suggest
antibodi
recogn
yet
undefin
epitop
partial
overlap
one
recogn
bind
block
antigen
site
iii
antibodi
reciproc
antibodi
block
bind
sever
antigen
site
iii
antibodi
interpret
competit
result
taken
account
two
epitop
overlap
even
area
cover
arm
two
antibodi
overlap
competit
almost
complet
mutual
thu
mark
mutual
taken
unequivoc
evid
overlap
epitop
sinc
weak
inhibit
may
simpli
reflect
decreas
affin
due
steric
alloster
effect
thu
latter
result
suggest
antibodi
form
third
cluster
recogn
distinct
hereaft
dub
antigen
site
three
addit
site
defin
name
b
c
site
defin
uniqu
antibodi
whose
bind
compromis
bind
major
label
antibodi
panel
reciproc
bind
label
block
antibodi
panel
result
might
suggest
bind
induc
alloster
effect
g
protein
compromis
bind
antibodi
site
b
defin
antibodi
whose
bind
block
antibodi
panel
similarli
site
c
defin
antibodi
also
recogn
uniqu
distinct
site
compar
antibodi
twelv
antibodi
select
test
base
neutral
potenc
recognit
distinct
site
rabv
g
protein
addit
hrig
includ
test
larg
panel
lyssavirus
use
pseudotyp
n
infecti
virus
n
cover
rabv
lbv
mokv
duvv
ablv
irkv
khuv
arav
shibv
bblv
ikov
wcbv
speci
fig
b
virus
neutral
ngml
score
posit
among
antigen
site
antibodi
test
pseudotyp
neutral
assay
wright
et
al
show
largest
breadth
reactiv
abl
neutral
phylogroup
virus
test
well
shibv
phylogroup
ii
ikov
put
phylogroup
iv
fig
comparison
antigen
site
antibodi
neutral
shibv
ikov
isol
test
infecti
virus
cliquet
et
al
warrel
et
al
broadli
neutral
rabv
duvv
ablv
bblv
isol
test
well
phylogroup
ii
mokv
fig
analysi
neutral
mokv
isol
among
antigen
site
iii
antibodi
test
pseudotyp
neutral
assay
potent
neutral
phylogroup
virus
ngml
comparison
antigen
site
iii
antibodi
less
broad
potent
unabl
neutral
test
test
infecti
virus
potent
neutral
phylogroup
virus
test
analysi
show
limit
breadth
neutral
note
antibodi
neutral
phylogroup
ii
pseudotyp
virus
test
wcbv
neutral
although
valu
higher
compar
fig
test
infecti
virus
antibodi
howev
abl
effect
ie
ngml
neutral
phylogroup
ii
isol
test
fig
limit
analysi
antibodi
breath
lyssavirus
antigen
site
iii
abl
neutral
lyssavirus
test
remark
phylogroup
lyssavirus
test
fig
comparison
antibodi
neutral
lyssavirus
phylogroup
lyssavirus
respect
analysi
show
antigen
site
abl
neutral
lyssavirus
phylogroup
lyssavirus
respect
contrast
antibodi
neutral
lyssavirus
phylogroup
lyssavirus
respect
combin
cover
lyssavirus
phylogroup
lyssavirus
respect
cover
lyssavirus
phylogroup
lyssavirus
respect
hrig
also
test
panel
pseudotyp
virus
cover
lyssavirus
phylogroup
lyssavirus
analysi
neutral
activ
antibodi
refer
antibodi
extend
larg
panel
rabv
isol
n
virus
pseudotyp
virus
repres
circul
lineag
ie
american
asian
cosmopolitan
africa
africa
lineag
fig
appendix
tabl
rabv
isol
effect
neutral
antibodi
valu
rang
ngml
comparison
neutral
rabv
test
significantli
lower
potenc
similar
hrig
neutral
larg
major
rabv
strain
test
narrow
rang
rang
ngml
importantli
show
broader
rang
valu
ngml
ngml
respect
neutral
six
three
rabv
isol
respect
ngml
concentr
like
effect
pep
analysi
extend
addit
rabv
isol
test
abil
antibodi
bind
g
cell
flow
cytometri
appendix
tabl
rabv
strain
recogn
bind
strain
thu
extend
number
isol
analyz
order
better
defin
epitop
specif
select
human
monoclon
antibodi
test
chimer
mutant
rabv
lbv
pseudotyp
virus
particular
amino
acid
chang
found
previous
describ
viral
escap
mutant
bakker
et
al
marissen
et
al
introduc
gene
correspond
mutant
pseudotyp
virus
produc
addit
chimer
pseudotyp
virus
call
gener
antigen
site
iii
residu
replac
correspond
residu
lbv
strain
fig
convers
antigen
site
iii
residu
lbv
replac
correspond
residu
gener
chimer
lbv
pseudotyp
virus
respect
similar
approach
use
antigen
site
iia
iib
iv
produc
pseudotyp
virus
case
antigen
site
kg
motif
conserv
lbv
two
alanin
residu
introduc
viru
gener
mutant
call
laa
panel
select
antibodi
well
refer
antibodi
test
abil
neutral
mutant
pseudotyp
virus
compar
correspond
parent
lbv
result
analysi
summar
fig
neutral
activ
abolish
antigen
site
lbv
swap
mutant
lbv
neutral
antibodi
chimer
lbv
pseudotyp
viru
carri
antigen
site
neutral
result
agreement
competit
result
shown
fig
confirm
recogn
epitop
antigen
site
rabv
g
protein
remain
antibodi
panel
test
chimer
pseudotyp
virus
neutral
activ
alter
compar
parent
lbv
virus
thu
confirm
antigen
site
part
epitop
final
antibodi
unabl
neutral
escap
mutant
result
indic
recogn
epitop
antigen
site
distinct
recogn
recogn
epitop
overlap
recogn
howev
find
broader
reactiv
lyssavirus
fig
compar
indic
antibodi
may
recogn
conserv
epitop
similarli
neutral
activ
abolish
antigen
site
iii
lbv
swap
mutant
lbv
neutral
antigen
site
iii
antibodi
chimer
lbv
pseudotyp
viru
carri
antigen
site
iii
neutral
effici
result
indic
antibodi
recogn
epitop
similar
recogn
case
antibodi
swap
antigen
site
iii
lbv
affect
neutral
activ
similar
antigen
site
iii
antibodi
describ
pseudotyp
viru
neutral
find
suggest
recognit
antigen
site
iii
residu
antibodi
suffici
neutral
chimer
lbv
also
epitop
rabv
form
addit
residu
surround
antigen
site
iii
final
case
antibodi
swap
antigen
site
iii
residu
lbv
result
partial
complet
loss
neutral
activ
thu
suggest
epitop
compris
addit
residu
antigen
site
iii
final
antibodi
includ
except
data
shown
abl
neutral
escap
mutant
thu
indic
mutat
block
bind
antibodi
cognat
epitop
context
protein
result
indic
antibodi
recogn
epitop
antigen
site
iii
similar
recogn
other
recogn
distinct
epitop
antigen
site
iii
region
addit
antibodi
panel
direct
antigen
site
iii
particular
show
greater
breadth
reactiv
lyssavirus
compar
fig
approach
lead
definit
epitop
recogn
antigen
site
b
c
antibodi
competit
result
shown
fig
result
antigen
site
swap
shown
fig
indic
bind
primarili
antigen
site
iii
respect
therefor
analyz
degre
conserv
antigen
site
iii
amino
acid
residu
sequenc
independ
rabv
isol
retriev
multipl
public
databas
repres
global
rabv
divers
fig
found
posit
antigen
site
polymorph
fig
test
neutral
lyssavirus
carri
leucin
serin
prolin
residu
posit
repres
rabv
analyz
fig
posit
lysin
virus
virus
carri
arginin
note
neutral
phylogroup
isol
carri
arginin
posit
thu
indic
presenc
arginin
posit
alway
suffici
case
fig
escap
neutral
analysi
indic
antibodi
epitop
highli
conserv
rabv
analysi
requir
investig
abil
neutral
field
isol
carri
arginin
posit
importantli
three
escap
mutant
neutral
effici
similar
analysi
perform
antigen
site
iii
antibodi
antigen
site
iii
primarili
form
residu
ksvrtwnei
consensu
sequenc
posit
rabv
g
protein
describ
antigen
site
therefor
analyz
degre
conserv
antigen
site
iii
amino
acid
residu
panel
rabv
isol
found
posit
highli
conserv
residu
polymorph
fig
recogn
rabv
isol
carri
multipl
residu
polymorph
posit
repres
least
rabv
analyz
fig
particular
rabv
isol
arginin
posit
sever
residu
found
posit
aspart
present
sever
phylogroup
ii
virus
neutral
final
neutral
lyssavirus
carri
either
asparagin
aspart
lysin
serin
posit
account
rabv
analyz
contrast
rabv
carri
aspart
posit
poorli
neutral
thu
indic
approxim
circul
rabv
might
resist
neutral
note
major
african
rabv
isol
analyz
carri
posit
appendix
tabl
isol
correspond
lineag
analysi
confirm
previou
neutral
result
neutral
phylogroup
lyssavirus
test
indic
epitop
highli
conserv
rabv
phylogroup
lyssavirus
investig
whether
antibodi
display
neutral
activ
lethal
rabv
infect
vivo
test
two
antibodi
syrian
hamster
mesocricetu
auratu
model
hanlon
et
al
briefli
anim
n
per
group
challeng
intramuscularli
lethal
dose
rabv
subsequ
receiv
prophylaxi
contain
either
hrig
pep
equimolar
cocktail
antibodi
expep
differ
concentr
mgkg
eleven
anim
treat
infect
succumb
day
fig
standard
prophylaxi
pep
effect
reduc
overal
mortal
anim
surviv
challeng
strikingli
combin
mgkg
correspond
administ
hrig
protect
anim
time
lower
dose
mgkg
protect
anim
suggest
mgkg
equival
mgkg
hrig
dose
determin
effect
antibodi
mixtur
vaccin
potenc
vivo
experi
perform
hamster
briefli
vaccin
immunogen
assess
serolog
test
presenc
hrig
cocktail
administr
result
demonstr
hrig
mgkg
mgkg
reduc
endogen
hamster
antibodi
respons
rabv
g
protein
fig
compar
anim
receiv
vaccin
alon
note
level
neutral
antibodi
anim
administ
antibodi
cocktail
mgkg
compar
elicit
vaccin
alon
standard
pep
vaccin
hrig
anim
neutral
titer
iuml
never
threshold
iuml
fig
final
high
level
human
antibodi
found
day
anim
treat
mgkg
hrig
mgkg
undetect
low
level
human
igg
found
sera
anim
treat
mgkg
fig
result
suggest
dose
mgkg
shown
protect
pep
compromis
product
antibodi
elicit
anim
upon
rabv
vaccin
sinc
first
gener
kohler
milstein
use
hybridoma
technolog
monoclon
antibodi
instrument
wide
rang
applic
research
diagnosi
therapi
cancer
well
inflammatori
infecti
diseas
studi
interrog
memori
repertoir
four
rabv
vaccin
presenc
serum
antibodi
capabl
broadli
neutral
multipl
lyssaviru
speci
isol
monoclon
antibodi
human
b
cell
alreadi
proven
success
identif
sever
broadli
neutral
antivir
antibodi
corti
lanzavecchia
could
use
probe
identifi
uniqu
epitop
design
new
vaccin
capabl
confer
broad
protect
also
develop
effect
conveni
diagnost
assay
analysi
specif
panel
human
neutral
antibodi
isol
studi
unveil
complex
antigen
lyssaviru
glycoprotein
new
epitop
like
involv
elicit
protect
host
immun
respons
addit
two
monoclon
antibodi
select
vivo
studi
ie
identifi
sever
other
interest
whose
specif
properti
requir
investig
note
one
antibodi
name
show
extraordinari
breadth
reactiv
across
phylogroup
ii
lyssavirus
recogn
linear
epitop
yet
determin
behr
kitasato
pioneer
use
passiv
antibodi
therapi
earli
show
approach
could
protect
diphtheria
tetanu
kitasato
although
therapi
base
anim
sera
shown
effect
diphtheria
infecti
diseas
use
associ
hypersensit
reaction
serum
sick
caus
larg
amount
anim
protein
reason
sever
case
cytomegaloviru
varicella
zoster
viru
hepat
b
viru
respiratori
syncyti
viru
develop
human
hyperimmun
immunoglobulin
prepar
prefer
case
rabi
sever
anim
studi
provid
evid
viru
serum
increas
incub
period
contribut
surviv
babe
lepp
habel
subsequ
studi
show
viru
serum
combin
vaccin
effici
vaccin
serum
alon
koprowski
et
al
determin
whether
combin
vaccin
serum
would
gener
similar
result
human
expert
committe
rabi
assess
seri
studi
role
serum
vaccin
import
studi
perform
iran
individu
bitten
rabid
wolf
demonstr
combin
serum
vaccin
given
within
day
exposur
clearli
effect
vaccin
alon
baltazard
bahmanyar
habel
sever
subsequ
studi
uninfect
individu
show
serum
antibodi
vaccin
reduc
activ
endogen
humor
respons
atanasiu
et
al
howev
booster
dose
vaccin
partli
overcam
interfer
wiktor
et
al
mechan
rig
action
base
passiv
antibodi
administr
confer
immedi
protect
neutral
rabi
viru
site
infect
unlik
vaccin
stimul
protect
immun
delay
howev
activ
immun
respons
stimul
vaccin
develop
absenc
spread
viru
cn
although
definit
protect
titer
defin
possibl
exposur
scenario
achiev
antibodi
titer
equal
iuml
consid
protect
threshold
achiev
day
begin
pep
repres
endpoint
ongo
phase
trial
monoclon
pep
bakker
et
al
man
et
al
previou
compar
studi
signific
differ
neutral
titer
elicit
vaccin
observ
either
mixtur
hrig
administ
accord
pep
protocol
goudsmit
et
al
similarli
antibodi
mixtur
mgkg
interfer
vaccin
respons
hamster
addit
found
neutral
antibodi
detect
peripher
blood
hamster
day
administr
either
hrig
mgkg
mainli
hamster
antibodi
deriv
endogen
immun
respons
fig
note
pep
antibodi
cocktail
mgkg
almost
fulli
clear
organ
day
administr
convers
happen
higher
dose
immunoglobulin
either
hrig
mgkg
mgkg
use
mgkg
antibodi
mixtur
although
endogen
respons
elicit
indic
interfer
monoclon
antibodi
vaccin
somehow
occur
hamster
still
high
neutral
titer
peripher
blood
day
administr
therefor
still
potenti
protect
lethal
rabv
challeng
find
certainli
deserv
investig
potenti
break
paradigm
prophylaxi
approach
base
ie
immedi
administr
rig
could
safe
delay
one
week
vaccin
time
administ
suppli
hrig
dwindl
due
difficulti
find
human
donor
expens
approxim
usd
per
adult
treatment
inde
million
dose
rig
million
erig
million
hrig
exclud
chines
domest
market
produc
sold
everi
year
peopl
categori
iii
exposur
receiv
rig
bourhi
et
al
erig
product
also
difficult
due
disappear
mani
local
produc
ethic
issu
product
condemn
anim
protect
group
lower
safeti
deriv
use
erig
compens
develop
f
erig
purifi
erig
favirab
howev
reduc
f
product
might
contribut
anecdot
pep
failur
ertl
relat
data
deriv
anim
studi
shown
intact
immunoglobulin
product
effect
rabi
pep
compris
f
fragment
hanlon
et
al
anoth
gener
drawback
rig
antibodi
small
proport
mani
antibodi
pathogen
specif
transit
rig
monoclon
pep
therefor
strongli
recommend
aim
achiev
adequ
suppli
reduct
product
cost
reduct
advers
reaction
risk
avail
consist
activ
batch
addit
sinc
monoclon
antibodi
come
form
concentr
product
effect
rig
wound
infiltr
therefor
reduc
introduct
excess
volum
site
intramuscular
inject
anoth
advantag
may
deriv
formul
studi
develop
monoclon
antibodi
highli
stabl
format
eg
lyophil
would
allow
storag
well
conveni
suppli
rural
area
accord
recommend
best
approach
replac
rig
monoclon
antibodi
base
develop
cocktail
antibodi
abl
reduc
risk
pep
failur
best
characterist
cocktail
antibodi
follow
high
potenc
ii
recognit
distinct
antigen
site
iii
high
breadth
reactiv
complet
coverag
field
rabv
isol
anoth
import
featur
activ
antibodi
form
cocktail
reli
synergist
effect
inde
although
synergi
may
result
potent
neutral
viru
harbor
epitop
individu
cocktail
antibodi
potenc
could
significantli
reduc
viru
epitop
avail
importantli
antibodi
show
synergist
neutral
activ
vitro
appendix
figur
studi
select
two
human
monoclon
antibodi
vaccine
abil
bind
two
distinct
antigen
site
site
iii
rabv
g
protein
addit
abl
potent
neutral
rabv
isol
panel
repres
lineag
phylogroup
isol
inde
identif
rare
broadli
reactiv
antibodi
select
studi
increas
barrier
occurr
resist
sinc
cope
higher
degre
variabl
cognat
epitop
regard
import
note
viral
escap
mutant
might
impair
vivo
fit
might
particularli
case
viral
escap
multipl
broadli
reactiv
antibodi
addit
import
featur
similar
hrig
abil
neutral
rabv
test
within
narrow
similar
rang
antibodi
concentr
contrast
previou
studi
found
antigen
site
antibodi
abl
neutral
virus
test
analysi
databas
isol
contain
mutat
would
like
abrog
bind
bakker
et
al
marissen
et
al
case
antigen
site
iii
antibodi
found
databas
rabv
isol
harbor
mutat
bakker
et
al
none
rabv
isol
carri
mutat
epitop
exist
natur
occur
strain
resist
one
two
antibodi
cocktail
higher
frequenc
endem
area
africa
second
highest
number
case
asia
pose
higher
risk
vivo
select
mutant
abl
escap
second
antibodi
thu
lead
potenti
risk
pep
failur
case
antibodi
current
test
phase
trial
india
singl
antibodi
two
isol
test
neutral
three
poorli
neutral
sloan
et
al
case
risk
pep
failur
least
principl
higher
case
antibodi
cocktail
result
suggest
limit
breadth
reactiv
toward
isol
signific
fraction
rabv
isol
test
poorli
neutral
antigen
site
iii
antibodi
also
import
note
analysi
differ
hrig
prepar
reveal
rabv
cover
particular
comparison
imogam
hrig
sanofi
bayrab
bayer
show
one
rabv
strain
bat
origin
neutral
bayrab
hrig
imogram
hrig
goudsmit
et
al
result
well
result
studi
brook
et
al
hanlon
et
al
horton
et
al
show
hrig
limit
efficaci
toward
isol
anoth
advantag
replac
hrig
cocktail
two
broadli
neutral
antibodi
repres
possibl
use
pep
phylogroup
isol
final
high
vitro
potenc
antibodi
vivo
result
present
studi
demonstr
limit
amount
antibodi
need
protect
lethal
infect
equival
mg
kg
adult
consid
mark
reduct
antibodi
product
cost
kelley
amount
would
compat
consider
lower
price
eg
us
dollar
antibodi
compar
hrig
conclus
combin
antibodi
repres
treatment
unpreced
breadth
potenc
develop
afford
product
replac
rig
rabi
pep
igg
memori
b
cell
isol
cryopreserv
pbmc
use
microbead
miltenyi
biotec
follow
deplet
cell
carri
igm
igd
iga
cell
sort
immort
ebv
cpg
multipl
replic
well
previous
describ
traggiai
et
al
cultur
supernat
test
abil
neutral
rabv
pseudotyp
viru
infect
assay
posit
cultur
collect
expand
posit
cultur
vh
vl
sequenc
retriev
antibodi
clone
human
ig
kappa
ig
lambda
express
vector
kindli
provid
michel
nussenzweig
rockefel
univers
new
york
ny
usa
essenti
describ
tiller
et
al
monoclon
antibodi
produc
b
cell
transient
transfect
freestyl
cell
invitrogen
supernat
b
cell
transfect
cell
collect
igg
affin
purifi
protein
protein
g
chromatographi
ge
healthcar
desalt
pb
human
embryon
kidney
clone
cell
hek
atcc
use
product
lentivir
pseudotyp
neutral
assay
undertaken
cell
clone
atcc
plate
pseudotyp
viru
result
output
rel
light
unit
rlu
incub
doubl
dilut
sera
antibodi
h
addit
cell
incub
h
supernat
remov
steadylit
reagent
perkin
elmer
ad
luciferas
activ
detect
min
later
read
plate
synergi
micropl
luminomet
biotek
wright
et
al
reduct
infect
determin
compar
rlu
presenc
absenc
antibodi
express
percentag
neutral
neutral
potenc
monoclon
antibodi
measur
defin
antibodi
concentr
rlu
reduc
compar
viru
control
well
subtract
background
rlu
cell
control
well
sera
dilut
sera
rlu
reduc
valu
sera
correspond
dilut
rlu
reduc
antigen
site
swap
access
access
g
gene
undertaken
use
overlap
pcr
heckman
peas
confirm
sequenc
analysi
result
g
gene
subsequ
use
gener
pseudotyp
virus
titrat
bhk
cell
ensur
mutat
affect
bind
entri
function
g
protein
standard
elisa
use
determin
bind
serum
antibodi
monoclon
antibodi
rabv
g
protein
briefli
elisa
plate
coat
rabv
g
protein
block
fc
pb
incub
sera
human
antibodi
wash
bound
antibodi
detect
incub
goat
igg
southern
biotech
plate
wash
substrat
sigma
ad
plate
read
nm
rel
affin
sera
bind
monoclon
antibodi
bind
determin
measur
dilut
sera
concentr
antibodi
requir
achiev
maxim
bind
satur
purifi
rabv
g
protein
prepar
accord
meslin
et
al
load
polyacrylamid
gel
protein
transfer
pvdf
membran
perform
iblot
blot
system
invitrogen
pvdf
membran
block
min
dri
milk
incub
primari
antibodi
g
protein
perform
overnight
pvdf
wash
three
time
incub
h
rt
igg
antibodi
ge
healthcar
pvdf
membran
wash
three
time
posit
band
detect
use
ecl
western
blot
detect
reagent
ge
healthcar
ccd
camera
system
antibodi
select
label
biotin
test
elisa
matrix
competit
assay
unlabel
antibodi
incub
first
concentr
rabv
g
plate
follow
addit
limit
concentr
biotinyl
antibodi
whose
bind
reveal
alkalin
streptavidin
interpret
competit
result
taken
account
two
epitop
overlap
area
cover
arm
two
antibodi
overlap
competit
almost
complet
weak
inhibitori
enhanc
effect
may
reflect
decreas
affin
owe
steric
alloster
effect
select
rabv
lyssavirus
initi
cultur
cell
atcc
cat
n
adapt
bsr
cell
clone
two
protocol
slightli
modifi
fluoresc
antibodi
viru
neutral
mfavn
rapid
fluoresc
foci
inhibit
mrffit
test
cliquet
et
al
warrel
et
al
respect
appli
test
potenc
antibodi
studi
work
stock
amplifi
titrat
either
bsr
accord
neutral
test
adopt
rffit
favn
respect
addit
standard
favn
rffit
assay
undertaken
assess
potenc
test
antibodi
briefli
mfavn
assay
base
standard
favn
undertaken
bsr
cell
sequenc
complet
g
gene
origin
specimen
well
lyssavirus
use
challeng
virus
vitro
assay
obtain
viral
rna
extract
use
nucleospin
rna
ii
kit
accord
manufactur
instruct
gmbh
co
germani
briefli
one
hundr
microlit
sampl
suspens
use
extract
rna
elut
final
volum
store
amplif
perform
use
qiagen
onestep
kit
qiagen
gmbh
hilden
germani
accord
manufactur
instruct
primer
use
amplif
complet
g
gene
sequenc
avail
upon
request
pcr
product
analyz
puriti
size
electrophoresi
agaros
gel
stain
gelredtm
nucleic
acid
gel
stain
biotium
hayward
ca
amplicon
subsequ
purifi
usb
corpor
cleveland
oh
sequenc
direct
use
big
dye
termin
cycl
sequenc
kit
appli
biosystem
foster
citi
ca
usa
product
sequenc
reaction
clean
use
performa
dtr
ultra
kit
edg
biosystem
gaithersburg
md
analyz
abi
prism
genet
analyz
appli
biosystem
foster
citi
ca
usa
occurr
differ
amino
acid
ident
antigen
site
antigen
site
iii
analyz
download
rabv
glycoprotein
sequenc
present
nation
center
biotechnolog
inform
ncbi
entrez
protein
databas
sayer
et
al
novemb
retriev
sequenc
purg
miss
complet
sequenc
amino
acid
posit
cover
antigen
site
iii
contain
ambigu
amino
acid
ident
lack
countri
origin
total
sequenc
sequenc
includ
sequenc
rabv
test
panel
align
use
mafft
katoh
standley
perform
amino
acid
distribut
analysi
algorithm
written
java
multipl
sequenc
align
amino
acid
sequenc
perform
full
length
sequenc
amino
acid
residu
length
use
clustal
omega
siever
higgin
phylogenet
analysi
sequenc
undertaken
use
maximum
likelihood
method
avail
phyml
packag
guindon
gascuel
analysi
util
lg
model
amino
acid
replac
gamma
distribut
rate
variat
blood
sampl
collect
particip
vaccin
rabi
donor
gave
written
inform
consent
research
use
blood
sampl
follow
approv
canton
ethic
committe
canton
ticino
switzerland
anim
studi
perform
strict
accord
relev
nation
local
anim
welfar
bodi
convent
european
council
nation
guidelin
legisl
decre
protocol
author
italian
ministri
health
decre
experi
initi
approv
committe
ethic
anim
experi
izsv
experi
perform
femal
spf
syrian
hamster
mesocricetu
auratu
week
age
averag
weight
g
charl
river
laboratori
anim
hous
individu
ventil
cage
three
individu
per
cage
temperatur
light
cycl
free
access
water
food
press
cotton
pad
mous
hous
litter
bag
use
environment
enrich
standard
rodent
feed
weekli
integr
autoclav
sunflow
seed
order
minim
effect
subject
bia
alloc
anim
randomli
assign
treatment
control
group
blind
investig
implement
sampl
anim
exclud
analys
syrian
hamster
challeng
day
intramuscular
rout
gastrocnemiu
muscl
right
hind
limb
ml
dilut
strain
anim
given
biolog
pb
neg
control
end
day
treat
group
n
commerci
vaccin
novarti
vaccin
diagnost
purifi
chick
embryo
cell
vaccin
contain
inactiv
rabi
viru
strain
fluri
lep
potenc
intern
unit
iu
administ
intramuscularli
im
left
hind
limb
day
pi
hyperimmun
treatment
consist
hrig
mgkg
equival
iukg
candid
antibodi
mgkg
mgkg
equimolar
mixtur
antibodi
administ
im
day
right
hind
limb
final
volum
challeng
anim
observ
twice
day
promptli
euthan
onset
one
clinic
sign
rabi
ie
motor
deficit
lack
coordin
paresi
paralysi
sensori
dull
central
nervou
system
cn
tissu
name
brain
cerebellum
brainstem
spinal
cord
collect
confirm
rabi
viru
infect
mean
standard
techniqu
fluoresc
antibodi
test
fat
oie
world
organ
anim
health
syrian
hamster
divid
four
group
n
per
group
vaccin
commerci
purifi
chicken
embryo
cell
vaccin
novarti
vaccin
diagnost
purifi
chick
embryo
cell
vaccin
contain
inactiv
rabi
viru
strain
fluri
lep
potenc
iu
vaccin
administ
day
im
left
hind
limb
three
group
concomitantli
administ
day
hrig
mgkg
equimolar
mixtur
mgkg
refer
hd
inject
im
right
hind
limb
right
left
hind
limb
hd
antibodi
cocktail
administr
sera
collect
anim
n
day
pv
test
favn
cliquet
et
al
presenc
rabi
neutral
antibodi
elisa
presenc
either
g
hamster
antibodi
residu
human
igg
number
individu
experiment
group
n
per
group
calcul
use
fisher
exact
condit
test
two
proport
implement
proc
power
twosamplefreq
sa
softwar
power
wilcoxon
test
use
analyz
differ
mean
valu
group
test
also
use
describ
legend
consid
statist
signific
pdb
ic
ala
hb
dc
conceiv
studi
pdb
rw
gc
ic
fs
ala
hb
dc
particip
studi
design
ga
fv
isol
monoclon
antibodi
ern
ra
bz
ga
fv
rl
ale
eb
ew
character
monoclon
antibodi
vitro
rl
mf
perform
analyz
viral
sequenc
pdb
ern
ra
perform
vivo
test
pdb
ew
ala
hb
dc
critic
analyz
data
pdb
ew
hb
dc
draft
manuscript
author
revis
accept
manuscript
present
form
pdb
ra
bz
gc
ic
employ
izsv
rl
ale
hb
employ
ga
fv
dc
employ
humab
biom
sa
ala
scientif
founder
humab
biom
sa
hold
share
humab
biom
sa
alter
adher
embo
press
journal
polici
share
data
materi
